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ABSTRACT
The purpose of this study was to investigate the efficacy of telegenetic services
for pediatric genetic evaluations conducted by telemedicine by comparing it to in-person
pediatric genetic evaluations. Research into the utility of telegenetics would greatly serve
to identify if this is a preferred alternative service delivery model to bridge the gap in
accessibility and reach a greater catchment area of the population, especially to those
living in underserved and rural locations. This study was a retrospective review of
electronic medical records of pediatric patients seen at Greenwood Genetic Center (GGC)
for initial in-person genetic visits prior to the COVID-19 pandemic and initial
telemedicine genetic visits during the COVID-19 pandemic. Primary indications were
reviewed in conjunction with the final clinical assessment made by the geneticist at the
time of visit. Diagnostic information from the clinical assessment was used to determine
if a clinical diagnosis could be made, which was categorized into clinical genetic
diagnosis (met clinical criteria with/without the need for molecular confirmation),
environmental etiology, isolated anomaly, multifactorial etiology, within normal
variation, and testing not indicated. If testing was indicated, results were categorized into
diagnosed, undiagnosed, uncertain, or not completed. Both clinical assessment and
genetic testing outcomes were used in the diagnostic yield comparison. We found that
visit type did not have a significant effect on the likelihood of diagnosis. Identifying the
similarities in diagnostic outcomes for patients seen by telemedicine may strengthen the
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support for telegenetic services, improve accessibility to genetic services, and benefit
both providers and patients.
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CHAPTER 1
INTRODUCTION
1.1 Current Genetic Testing Protocols and Diagnostic Yield in Pediatric Patients
Pediatric genetic evaluations aim to provide a specific diagnosis for noted signs
and symptoms and these evaluations often include physical exam, history, and genetic
testing. Although there are various referral indications for patients seen for a pediatric
genetic evaluation, the most common indications include developmental delay (DD),
intellectual disability (ID), autism spectrum disorder (ASD), and multiple congenital
anomalies (MCA); the current standard of practice for individuals with these indications
is chromosomal microarray (CMA) as a first-line test (Manning et al., 2010; South et al.,
2013). CMA is further recommended as a first-tier test for individuals with features not
specific to a well-delineated genetic syndrome. The current literature suggests CMA has
a diagnostic yield for individuals with unexplained DD/ID, ASD, or MCAs of around 1520%; this is higher than the ~3% diagnostic yield from karyotype, which is more likely to
identify recognizable chromosomal syndromes (Miller et al., 2010). The current
guidelines suggest a more targeted testing strategy is recommended for individuals who
have a specific phenotype suggestive of a known genetic condition. For these patients, a
more targeted gene sequencing panel may be a more cost-effective method in establishing
a genetic diagnosis (Kiely et al., 2016; Retterer et al., 2016; Vissers et al., 2017).
Since the American College of Medical Genetics and Genomics (ACMG)
published the practice guidelines for the use of CMA as a first-tier test, technology has
1

greatly improved and whole exome sequencing (WES) has enabled additional diagnoses
in patients not diagnosed by CMA or other testing methods (South et al., 2013).
Beginning in 2011, literature has suggested that WES should be considered as a first-tier
test for certain indications due to a potentially higher yield than CMA, with a diagnostic
yield of at least 25% (Clark et al., 2018; Retterer et al., 2016; Vissers et al., 2017).
Guidelines currently do not exist for the use of WES as a first-tier test, largely due to the
need for more research on the impact of results on clinical management in order to
establish clinical utility and develop standardized guidelines (Malinowski et al., 2020).
Since there have been few changes to the guidelines, CMA remains the recommendation
for first-line testing for individuals with non-specific DD/ID, ASD, and MCAs. Due to an
overwhelming amount of literature suggesting the value of WES in determining a genetic
etiology, WES is generally considered a good option as a second-tier test for those who
do not receive a diagnosis after first-line testing.
With a number of professional societies recognizing the importance of genetic
testing in the etiologic workup for children with DD/ID and ASD, guidelines published
by the American Academy of Pediatrics (AAP), the American Academy of Neurology,
and the ACMG all recommend CMA and Fragile X testing as first-tier diagnostic tests for
children with unexplained DD/ID with or without ASD (Filipek et al., 2000; Miller et al.,
2010; Moeschler et al., 2014; South et al., 2013). It is suggested that more targeted testing
or karyotype may be indicated following a physical exam, if family history is suggestive
of a specific diagnosis, or if initial testing fails to establish a genetic diagnosis. With this
approach, the identification of an underlying genetic cause may be found in up to 40% of
patients (Kiely et al., 2016).
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Vissers et al. (2017) reported data that suggest WES as a preferred first-tier
diagnostic test in patients with complex neurological features in order to shorten time-todiagnosis as well as reduce costs for unnecessary procedures, imaging studies, biopsies,
etc. Although single gene testing and gene panels are commonly used when a specific
disorder associated with a small number of genes is suspected, WES has become an
advantageous testing strategy for patients with suspected disorders that are genetically
heterogenous (Retterer et al., 2016). The clinical application of broader tests such as
WES has been investigated to determine the utility in a broader range of clinical
indications, outside neurodevelopmental disorders, DD/ID, ASD, and MCAs. In a recent
study identifying the test yield based on primary indication, hearing, vision, skeletal
muscle, and skeletal indications were some of the highest yielding diagnostic outcomes
for WES (Retterer et al., 2016).
Due to the various referral indications for patients to be seen for a genetic
evaluation, there may be clearer guidelines on testing strategy for some patients than
there would be for other patients. This indicates that genetic providers may have different
testing approaches based on indication. Additionally, the diagnostic yield of WES
increases when trio testing (typically proband with both parents) is ordered versus testing
ordered just on the proband (Miller et al., 2010; Retterer et al., 2016). Often, the price of
testing increases with the inclusion of additional family members for genetic testing, so
there may be variation between providers on the inclusion of family members if the cost
or logistics to obtain samples are significant. The variation in testing strategy between
providers may determine a different diagnostic yield, with various extrinsic factors such
as insurance coverage and cost of testing playing a large role in the ability to order the
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preferred test. Some insurance policies have their own established guidelines that can
impact a provider’s testing strategy and may limit testing options.
Despite the number of societies recognizing the importance of genetic testing in
children with development disabilities, Kiely et al. (2016) sought to determine the rate at
which these children undergo genetic testing. They found that less than one-third of
individuals with ID, DD, and/or ASD have ever undergone genetic testing. Although this
study did not assess the reasons why children did or did not undergo genetic testing, there
were a number of factors proposed that may have contributed to their findings. One
finding of interest to this project was that children who were reported to have seen all
needed service providers within the year were more likely to have undergone testing than
those who did not. This finding suggests a broader issue in access to healthcare and that
difficulty obtaining genetic services may be contributing to the lower rate of testing in
individuals with developmental disabilities who should be offered testing. Potential
barriers such as lack of adequate transportation and access to care may also be
contributing to the underutilization of genetic testing in this population (Kiely et al.,
2016).
1.2 Disparity in access to genetic services
Access is an important concept in healthcare and has prompted innovation,
technology, and the development of alternative services to minimize the inequality that
can be seen across a variety of contributing factors. Access is most frequently considered
the ability or willingness to enter the health system, and includes specific areas that
contribute to the concept of access such as: availability, accessibility, accommodation,
and affordability (Penchansky & Thomas, 1981). Availability involves the supply and
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number of existing services, while accessibility is associated with the location and
distance required to obtain services. Accommodation refers to the relationship between
the organization of services offered as well as the perception of appropriate services
provided, and affordability is referred to as the ability to pay for services (Penchansky &
Thomas, 1981). Although we will not directly analyze costs or affordability (because data
collected would falsely represent services due to the current policy changes under the
1135 waiver, which allows Medicare beneficiaries to receive a wide range of previously
unavailable telehealth services), we hope to address and expose other areas addressed
above in minimizing the disparities in access to genetic services.
Much of the disparity and inequity in services can be attributed to a shortage in
genetics providers, with most practicing in cities serving large geographic areas, which in
turn can require some patients to travel far distances for genetics services. Rural and
underserved areas are frequently impacted as they are less likely to have adequate access
to reliable public transit, may be impacted by longer wait times for outreach clinics, or be
required to travel far distances for services. This can put a significant burden on both the
provider and families seeking services. The inaccessibility of genetics services in a
pediatric setting means that many children with genetic conditions will receive a delayed
diagnosis or remain undiagnosed. This is concerning, as a genetic diagnosis may alter
medical management and/or provide access to therapies that could benefit the patient and
the family (Lea et al., 2005; Penon-Portmann et al., 2019).
Geographic distance between a patient population and the nearest genetics
provider is an issue that is not limited to the United States and has been addressed in
other countries through the expanded use of telegenetics services, which is the use of
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telehealth in providing genetic services (Hopper et al., 2011; Otten et al., 2016; Pestoff et
al., 2019). However, there are considerable issues in the United States with
maldistribution of genetics professionals concentrated in large cities. Practice limitations
and insurance restrictions are a state-by-state issue and can be particularly burdensome
for larger states where significant portions of the population may be impacted by poverty
or live in rural areas (Lea et al., 2005; Penon-Portmann et al., 2019).
A study in California reported a provider to patient ratio of 1:330,000 for medical
geneticists and 1:100,000 for genetic counselors (Penon-Portmann et al., 2019). These
numbers highlight the challenges regarding geographic distribution in relation to the
genetics workforce shortage. For this particular study, analyzing zip code data revealed
that the average distance patients were traveling to be seen by a genetics provider was
76.6 miles. The authors further determined the role insurance may have in how far a
patient may need to travel, and identified that the median distance traveled for publicly
insured individuals was greater than that of privately insured individuals (public= 69.3
miles; private= 45.2 miles), with 71.4% of people traveling from rural locations having
public insurance (Penon-Portmann et al., 2019). This emphasizes the need to minimize
the limitations that travel may impose on families seeking a genetics evaluation.
Telegenetics may address some of the concerns with distance; half of genetics specialists
providing telemedicine estimate their geographic reach to be greater than 200 miles
(Terry et al., 2019).
Additionally, one of the proposed advantages of telegenetics is the effect it may
have on long wait times for genetics evaluations (Kubendran et al., 2017). Long wait
times can be anxiety-provoking for families seeking a diagnosis and may delay impactful
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medical management changes that would come from receiving a diagnosis. The use of a
collaborative service delivery model, including a pediatrician and genetic counselor, has
been used as an approach to provide telegenetics services to underserved areas, while also
decreasing the wait time for an appointment (Kubendran et al., 2017). Similarly, it was
found in other research utilizing a delivery model including a pediatrician and genetic
counselor, that over two years, the wait time for a genetics evaluation was reduced from
16.9 months to 3 months (Stalker et al., 2006). Receiving a timely diagnosis can have a
substantial impact on a patient and family as a diagnosis may provide additional
recommendations for services, screenings, and/or treatment.
As the field of genetics advances, so does the technology and ability to diagnose
and treat patients with genetic conditions. With this in mind, equity of access and quality
of services provided is imperative. More research is needed in determining the diagnostic
outcome and evaluating best practice models in making alternative services as
comparable as possible to that of an in-person evaluation.
1.3 What is telemedicine and what is its role in genetics?
Telemedicine can be defined as the use of electronic and communication
technology in patient care for diagnosis, monitoring, and therapy (Pestoff et al., 2019;
Vrečar et al., 2017). Over the past few decades, telemedicine was broadened to include
telehealth, which is characterized by the geographic separation between patient and
provider; however, both terms are used interchangeably (Wade et al., 2010). An increased
interest in the use of telehealth has developed over the past 20 years across several
medical specialties. Much of this interest arises from the need to make patient care more
accessible, especially when there are a limited number of specialty providers or an
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uneven geographic distribution of physicians. Addressing challenges in access to care
will require innovative technologies and/or service delivery models to improve access to
genetics services in remote or underserved areas.
Currently, there are four modalities that encompass ways of delivering
telemedicine: store-and-forward, remote patient monitoring, mobile health (mHealth),
and live video (Vrečar et al., 2017). Store-and-forward can be defined as the transmission
of recorded health information to a practitioner, such as sending digital X-ray images to a
radiologist. Remote patient monitoring technology is the collection of electronic
information transmitted from a patient and sent to a provider in a different location.
Mobile health (mHealth) incorporates the use of cell phones or tablets to provide
healthcare and education. Live video (synchronous) technology uses audio and
videoconferencing to provide interaction between the patient and provider (Vrečar et al.,
2017).
Of the modalities described, the most commonly used by genetics professionals is
live videoconferencing to provide real-time counseling or genetic evaluations, which is
also referred to as telegenetics. Although store-and-forward and mHealth have been
described in the literature as potentially useful for the field of genetics, live video
conferencing is the one that has been suggested as a potentially viable alternative to an
in-person genetic consultation (Vrečar et al., 2017).
As our knowledge of genetics and the role it plays in our understanding of disease
continues to expand, so does the number of patients who require genetic services. This
has profoundly influenced the increased interest in delivery of telehealth in genetics, or
often referenced as telegenetics, as an additional option for patients. While this is easier
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for providers who are not performing a physical exam, such as in cancer or prenatal
genetics, telegenetics is an area that needs further exploration in pediatric and general
genetics clinics. A recent study highlighted the need for a better understanding of the
current landscape of telegenetics, various delivery models, and the number of programs
utilizing videoconferencing for appointments (Terry et al., 2019). The authors surveyed
different sites that defined themselves as telegenetics programs and found that 31% of
respondents indicated they provided pediatric services by telemedicine, with only 6%
including provider consults. Of the 51 self-defined telegenetics programs, 32 sites were
using videoconferencing, 8 programs were using telephone technology, 2 programs
reported the use of store-and-forward, and the remaining 9 programs were currently
planning their programs to focus on the use of videoconferencing technology (Terry et
al., 2019). While most refer to telegenetics as real-time videoconferencing appointments,
it is important to note that telegenetics is an expanding field with a broad definition,
similar to that of telemedicine and telehealth.
1.4 Telegenetics satisfaction
Numerous studies have reported high patient satisfaction with no significant
difference between those patients seen by telegenetics and those seen in-person. Although
a majority of the research has been conducted in a prenatal or cancer setting, all have had
similar findings and have reported high patient and provider satisfaction (Buchanan et al.,
2015; Cohen et al., 2016; Hilgart et al., 2012; Otten et al., 2016). In a review of
telemedicine in genetics services, 14 articles reporting data from 12 different studies were
analyzed to determine what conclusions can be drawn on the value of telegenetics; not
only did all studies confirm previous reports of high levels of satisfaction, but they also
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reported patients found telemedicine services to be valuable in receiving care (Hilgart et
al., 2012). Where a comparison group was utilized, the level of satisfaction between the
groups was not significantly different (Hilgart et al., 2012).
Pediatric telegenetics research has reported similar findings in the satisfaction of
patients, pediatricians, and genetics providers (Hilgart et al., 2012; Hopper et al., 2011;
Lea et al., 2005). Difficulty with persuading children to cooperate during a telegenetics
visit has been referenced, yet this did not lower the overall reported satisfaction from the
families surveyed (Hopper et al., 2011). Despite additional levels of complexity in a
pediatric setting, which can include the need for children to cooperate when conducting a
dysmorphology exam, all findings have been fairly consistent across the different
specialties in genetics. This may be attributed to the perceived benefits of a telegenetics
visit outweighing the challenges. A two year study on improving patient access by
offering a telegenetics clinic in northwestern Florida found that 98% of patients strongly
disagreed with preferring to wait for a face-to-face appointment (Stalker et al., 2006). In
this same study, videoconferencing evaluations were able to decrease the wait time from
16.9 months to 3 months, which supports the overall benefits of telemedicine
outweighing the limitations.
Additional qualitative studies have been conducted to address some of the initial
concerns in the literature from many genetic counselors regarding the ability to
effectively address psychosocial concerns through videoconferencing. Otten et al. (2016)
conducted a study in the Netherlands looking at pre-symptomatic cardiac and cancer
patients to further examine telegenetics counseling sessions that had taken place to the
patient’s home. They administered pre- and post-counseling questionnaires, which
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revealed significantly higher satisfaction among those receiving counseling to the home
and no significant difference reported in psychological outcome (Otten et al., 2016). This
provides further evidence that the convenience and comfort of telegenetics visits to the
home surpasses any limitations.
1.5 The use of telegenetics in pediatric genetics
Few studies have focused on the use of telegenetics in pediatric genetics
evaluations. Of those reported, different delivery models were used in how the
appointment was conducted, with a majority focusing on alternative models to improve
timely access to genetics consultations and determine the effectiveness of telegenetics
(Hilgart et al., 2012). One of the critical components for a pediatric evaluation includes a
dysmorphology exam by a clinical geneticist. Questions have been raised about the
effectiveness of a telegenetics evaluation in a pediatric setting where a physical exam is
needed, and more research is needed on the diagnostic outcome. Of the few studies that
have focused on the diagnostic effectiveness of a dysmorphology exam, minimal
morphological findings were missed on a virtual exam, and no new diagnoses were made
in-person that had not been identified during the telegenetics evaluation (Lea et al., 2005;
Stalker et al., 2006). One study that included referring provider surveys did, however,
find that one referring pediatrician noted that some dysmorphology features were missed
in the telemedicine examination (Hopper et al., 2011).
Other studies have focused primarily on improving access to rural and
underserved areas where there may be restricted access and maldistribution of genetics
providers (Hopper et al., 2011; Kubendran et al., 2017; Lea et al., 2005). The ability to
perform dysmorphology examinations from a distance is valuable in rapidly identifying
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genetic conditions and improving timely access to genetic testing (Kubendran et al.,
2017; Lea et al., 2005). Although this research suggests telegenetics as a viable solution
in serving this patient population, it was not designed to evaluate the diagnostic yield for
these pediatric patients.
The literature on the diagnostic efficacy of a pediatric telegenetics evaluation is
scarce and the use of this modality seems to be underutilized in a pediatric setting. A
recent study investigating the rapid implementation of telemedicine during COVID-19related closures for a piloted program by the Division of Genetics and Metabolism at
Children’s National Hospital in Washington, D.C. provided initial data on visit numbers,
types of diagnoses, and no-show rates before and during the 2020-2021 pandemic. As
with many other telemedicine studies, common themes in their reason for investigation
included minimizing delays in time from presentation to diagnosis (due to barriers in
accessing genetic services), decreasing missed work, improving scheduling, and avoiding
transport and exposure of medically fragile patients. Based on pre-COVID-19 and postCOVID-19 data, the demographics and types of diagnoses for their patients were very
similar. Cited challenges included scheduling issues, technical problems, and licensure
regulations that were most significant the first week of the transition. One limitation that
is worth noting from this study was the accuracy of diagnostic decisions from
telemedicine visits compared with in-person visits, with 50% of participating centers
delaying scheduling or receiving results of investigational services (laboratory or
radiological) and 31% of centers reporting manufacturer supply of specialized chemicals,
kits, or consumables needed for diagnostic services was interrupted during the target
period of this study. It was concluded that rapid implementation was a sustainable and
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effective approach for delivery of services with high patient satisfaction rates. Despite
positive feedback and beneficial outcomes, the researchers indicated future studies are
needed in comparing diagnostic sequencing, biochemical testing, and hospitalization visit
rates between patients seen by telegenetics to patients seen in-person (Shur et al., 2020).
With advancements in technology and an increase in the need for genetics
services in underserved areas, it is important to identify how best to implement
telegenetics in practice. Determining gaps, if any, in diagnostic outcome will be useful in
developing well-defined guidelines and protocols in implementing telegenetics programs
and alternative service delivery for patients and families.
1.6 Reimbursement for telegenetics services before COVID-19
One of the primary limitations affecting the implementation of telegenetics may
be attributed to inadequate reimbursement from health insurers when compared to inperson evaluations. Much of the research conducted on large scale implementations of
regional telegenetics programs was supported by funding or grants that enabled program
development; however, all have cited continued funding as a limiting factor in the
sustainability of telegenetics programs (Hilgart et al., 2012; Lea et al., 2005; Terry et al.,
2019). Lower rates of reimbursement for telephone consultations have been reported by
genetic counselors as an issue and is likely due to telehealth policies, where video
consultations are eligible for insurance reimbursement, while telephone consultations are
usually not (Terry et al., 2019). In one study, only 47% of video-capable programs billed
insurance for services (Stalker et al., 2006; Terry et al., 2019).
While precise billing practices and reimbursement research in telegenetics is
lacking, other specialties utilizing telemedicine have reportedly experienced similar
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reimbursement issues. One study identified claims data from private insurers for mental
health and substance abuse appointments by telehealth and found that the average
reimbursement for appointments, which were based on diagnosis (ICD9) and procedure
(CPT) codes, were half that of patients provided the same services in a face-to-face visit
(Wilson et al., 2017). The results of the study imply that providers are less incentivized to
offer or use telehealth even if it may improve patient outcomes, which reflects a similar
theme in the literature about telegenetics programs.
In a 2012 systematic review reporting on research in 14 articles, none of the
studies formally measured the cost or reimbursement of telegenetics services, despite
citing that as a necessity in sustaining telegenetics programs in the future (Hilgart et al.,
2012). It also concluded a need for telegenetics support from not only private insurers,
but also Medicaid and Medicare. The demonstration of clinical effectiveness and
improved patient outcomes is necessary to encourage reimbursement for all telegenetics
services in the future (Hilgart et al., 2012).
While some private insurers have provided reimbursement for telehealth visits
using live synchronous videoconferencing, it has historically been reimbursed at a lower
rate than face-to-face visits. Centers for Medicare and Medicaid Services (CMS) has had
strict requirements for telehealth eligibility, with federal Medicaid guidelines not
recognizing telemedicine as a distinct service and only a small number of Medicare
beneficiaries meeting the criteria to be eligible for telemedicine (Centers for Medicare
and Medicaid Services, 2020). State Medicaid programs, on the other hand, vary in
recognizing telehealth visits and providing reimbursement for services. This is important
to acknowledge when considering the limitations of implementing telemedicine
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programs. In 2017, one study concluded Medicare has a quantitatively substantial
influence over private insurers’ payment of services (Clemens & Gottlieb, 2017).
Considering the influence Medicare has on private insurer coverage and reimbursement,
the widespread expansion of telehealth services is unlikely without federal recognition
and expansion of eligible telehealth services to be reimbursed at parity with in-person
visits.
1.7 CMS: Expansion of telehealth following the public health emergency, COVID-19
Medicare and Medicaid telehealth reimbursement policy is typically made up of
the following elements: where the patient is located during the telehealth visit, what
modality is being used to deliver the telehealth services, who or what type of provider is
delivering telehealth services, and what service is being delivered. The federal actions
that have been made to telehealth reimbursement policy usually center on these four
issues, which have largely expanded to accommodate more leniency during the public
health emergency (PHE) during COVID-19. Consequently, a majority of these changes
are temporary and need to be renewed before the expansion of these telehealth policy
changes are set to expire, with the most recent renewal extending through the entirety of
2021 (Center for Connected Health Policy, 2021).
Inadequate reimbursement, or no reimbursement at all, has been previously
reported as a challenge for healthcare systems looking to implement telemedicine as a
service delivery model to improve patient access to genetic services (Hilgart et al., 2012;
Terry et al., 2019). In response to the COVID-19 epidemic, CMS has temporarily
expanded telehealth services eligible to patients. CMS has issued policy changes under
the 1135 waiver which allows Medicare beneficiaries to receive a wide range of
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telehealth services that were previously unavailable. For example, one major element that
has allowed for expansion of services has been the temporary waiver of patient location
by Medicare and Medicaid that has allowed patients to receive telehealth services to their
home. Prior to the PHE, patients were limited to select sites that they would still have to
travel to in order to be seen virtually by a provider in a separate location. Additionally,
Medicare had separate geographic and service limitations that only covered select
telehealth services to patients in rural locations. The Department of Health and Human
Services (HHS) has issued recommendations under the 1135 waiver for the expansion of
coverage for state Medicaid programs to give providers flexibility in service delivery to
ensure Medicaid beneficiaries have access to care during the ongoing public health
emergency (Centers for Medicare and Medicaid Services, 2020).
CMS has included the following statement on their website:
Telehealth, telemedicine, and related terms generally refer to the exchange
of medical information from one site to another through electronic
communication to improve a patient’s health. Innovative uses of this kind
of technology in the provision of healthcare is increasing. And with the
emergence of the virus causing the disease COVID-19, there is an urgency
to expand the use of technology to help people who need routine care
(CMS.gov, 2020).
Under these circumstances, it is critically important to fully evaluate the
effectiveness of telehealth as a comparable alternative service to provide patients in the
future, especially since the current expansion under the 1135 waiver is temporary, and
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reimbursement, funding, and finances may once again serve as a barrier for telehealth
despite the proposed benefits for patients.
With both federal and private insurance policies adjusting their coverage benefits
to include and emphasize the use of telehealth for patient evaluations, we were able to
study and compare patients seen in-person before the COVID-19 policy changes and after
the restrictions were waived, allowing the increase of patients seen virtually. A
quantifiable comparison is beneficial to the field of genetics to determine best practices in
offering alternative methods to provide services to patients and consider the expansion of
telehealth for genetic evaluations as a way to improve patient access. Many permanent
changes have been made to CMS policy to expand telehealth coverage; however, for
more widespread permanent changes to be made on the federal level, congressional
action would be required. Therefore, it is necessary to quantifiably identify the
similarities or differences in diagnostic outcome for patients who are seen virtually, as
well as address additionally referenced advantages and limitations of telehealth services
for patients. Furthermore, as COVID-19 has impacted patient contact and service
delivery, it is important to identify if there are significant differences that should be
addressed in future follow-up with patients seen virtually during this time.
1.8 Rationale of Study
Accessibility has been a widely reported issue across many medical specialties,
and lower accessibility has been cited to include many factors such as provider shortages,
patients living in rural or underserved geographic locations, transportation issues,
inability to take time off work, etc. Telemedicine has been proposed as an alternative
service to in-person evaluations to reduce this disparity and provide services to a larger
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proportion of the population. Additionally, it has been utilized as an alternative method in
seeing patients during the ongoing PHE, where limitations on non-emergency physical
interaction has been recommended in order to prevent further transmission and spread of
COVID-19.
Greenwood Genetic Center (GGC) has historically provided in-person evaluations
by a clinical geneticist, but in response to the COVID-19 pandemic, GGC restricted inperson visits beginning on March 16, 2020, and transitioned to virtual visits (telemedicine
to the patient’s home) the week of March 30th. We evaluated new general genetics visits
across three GGC offices in South Carolina and compared results between in-person
(January and February 2020) and virtual visits (April and May 2020). The month of
March was omitted due to transitioning all in-person appointments to virtual visits.
Patient electronic medical records were reviewed to determine primary indication, testing
ordered, and diagnostic outcomes.
Telemedicine is appealing to many clinicians that feel these services have the
potential to minimize many of the current issues experienced by clinical genetics
providers, including: no-show rates, wait times for an evaluation, and the direct and
indirect costs to patients (travel time, taking time off work, etc). In fact, many of these
benefits have been previously reported when patients are provided a telemedicine option,
which has included an increase in efficiency, high patient satisfaction, decrease in wait
times for an evaluation, and decrease in distance required for patient travel (Hilgart et al.,
2012; Hopper et al., 2011; Lea et al., 2005; Stalker et al., 2006). However, much of the
literature is lacking in analyzing differences and similarities by comparing in-person and
pediatric telegenetic evaluations with a physical exam by a clinical geneticist. Therefore,
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a quantifiable comparison is necessary to assess the similarities and/or differences in
diagnostic outcome for patients who are seen by telemedicine when compared to those
seen in-person. The aim of this study was to help provide a foundation in determining
best practices in offering telegenetics as an alternative service delivery model and
highlight considerations in the expansion of telegenetic evaluations as a way to improve
patient access.
1.9 Objectives
1. Determine if there is a significant difference in diagnostic yield between pediatric
patients seen by a clinical geneticist in-person when compared to patients seen by
a clinical geneticist virtually by telemedicine to the patient’s home.
a. Analyze Clinical Assessment outcomes by comparing the number of
patients with an outcome of: Clinical Genetic Diagnosis (met clinical
criteria with/without the need for molecular confirmation), Environmental
Etiology, Multifactorial Etiology, Isolated Anomaly, Within Normal
Variation, and Testing Not Indicated
b. For patients categorized as Testing Indicated within the Clinical
Assessment outcome, identify and compare the diagnostic yield based on
genetic testing results by ascertaining and categorizing results as
Diagnostic, Undiagnosed, or Uncertain.
c. Assess and compare the total number of in-person patients vs.
telemedicine patients who received a diagnosis, either based on clinical
assessment or genetic testing results.
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2. Identify and compare the likelihood a diagnosis is made based on primary
indication.
a. Determine if providers were more or less likely to make a clinical
diagnosis based on primary indication between in-person and telemedicine
visits.
b. Determine if providers were more or less likely to make a
molecular/cytogenetic diagnosis based on primary indication between inperson and telemedicine visits.
c. Evaluate if categorical primary indications (Neurodevelopmental
Disorders, Structural Anomalies, Neurological Features, Additional
Features, and Suspected Genetic Disorder/Known Family History of
Genetic Disease) affected diagnostic outcomes and ensure populations
were comparable in complexity.
1.10 Hypothesis
There will not be a significant difference in diagnostic yield between pediatric
patients seen in-person when compared to those seen by telemedicine for a genetic
evaluation. It is suspected that there will be differences in the likelihood a diagnosis is
obtained based on primary indication; however, the variation of primary indications for
patients will not differ between the telemedicine and in-person cohorts. Lastly, the testing
strategy as well as the likelihood of second-tier testing and the number of those with a
testing outcome categorized as Not Completed will vary between those seen in-person
when compared to those seen by telemedicine.
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CHAPTER 2
EFFICACY OF TELEGENETICS: A DIAGNOSTIC YIELD
COMPARISON BETWEEN IN-PERSON AND TELEMEDICINE
PEDIATRIC GENETIC EVALUATIONS1

Merrihew, A., Lyons, M., Stallworth, J., Drazba, K., Abramson, R. To be submitted to
Genetics in Medicine.
1
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2.1 Abstract
The purpose of this study was to investigate the efficacy of telegenetic services
for pediatric genetic evaluations conducted by telemedicine by comparing it to in-person
pediatric genetic evaluations. Research into the utility of telegenetics would greatly serve
to identify if this is a preferred alternative service delivery model to bridge the gap in
accessibility and reach a greater catchment area of the population, especially to those
living in underserved and rural locations. This study was a retrospective review of
electronic medical records of pediatric patients seen at Greenwood Genetic Center (GGC)
for initial in-person genetic visits prior to the COVID-19 pandemic and initial
telemedicine genetic visits during the COVID-19 pandemic. Primary indications were
reviewed in conjunction with the final clinical assessment made by the geneticist at the
time of visit. Diagnostic information from the clinical assessment was used to determine
if a clinical diagnosis could be made, which was categorized into clinical genetic
diagnosis (met clinical criteria with/without the need for molecular confirmation),
environmental etiology, isolated anomaly, multifactorial etiology, within normal
variation, and testing not indicated. If testing was indicated, results were categorized into
diagnosed, undiagnosed, uncertain, or not completed. Both clinical assessment and
genetic testing outcomes were used in the diagnostic yield comparison. We found that
visit type did not have a significant effect on the likelihood of diagnosis. Identifying the
similarities in diagnostic outcomes for patients seen by telemedicine may strengthen the
support for telegenetic services, improve accessibility to genetic services, and benefit
both providers and patients.
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2.2 Introduction
As the demand for genetic services continues to grow, it is imperative that genetic
services are accessible to all patients seeking genetic evaluations, counseling, and
appropriate genetic testing. As with many other healthcare services, the current demand
far exceeds the number of qualified providers. This challenge, in conjunction with long
wait times for appointments and oftentimes long distances to travel for patients seeking
an appointment, need to be addressed with alternative service delivery models in order to
ensure equity of care for underserved populations. Telemedicine has been suggested as
one service delivery method proposed to remedy these challenges and the potential
benefits of the use of telemedicine services has been an area of interest across all medical
specialties. Continued research into the utility of telemedicine in genetics would greatly
serve to identify if this is a beneficial alternative service delivery model to bridge the gap
in accessibility and reach a greater catchment area of the population, especially to those
living in underserved and rural locations.
With the recent outbreak of COVID-19, telemedicine has become a more
common way to continue providing services to patients while minimizing the risk of
disease transmission and maintaining social distancing recommendations. The Centers for
Medicare and Medicaid Services (CMS) expanded coverage and reimbursement of
telemedicine services to provide alternative appointment options for patients and
providers so that they may comply with safety standards and social distancing
recommendations, while maintaining the ability to offer clinical services to patients.
Research into the benefits and drawbacks for patients seen for a genetics
evaluation by telemedicine will provide useful insight into who may best benefit from
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this alternative service delivery model. Additionally, some providers have reported that
their hesitancy in using telemedicine in genetics is the inability to pick up on
psychosocial cues, visualize the patient clearly, and perform an adequate physical exam.
However, many providers also report that the perceived benefits outweigh the concerns
(Cohen et al., 2016; Hilgart et al., 2012). Due to clear and established genetic testing
guidelines for children with neurodevelopmental delays, multiple congenital anomalies,
and intellectual disabilities, it is assumed that the testing strategy would be similar
regardless of being able to visualize the patient clearly. Alternatively, some providers
may not rely so much on the physical evaluation for testing indications such as nonsyndromic epilepsy, where previous imaging/testing such as an MRI or EEG may be
more important in determining the best testing indicated. Clearly visualizing a patient and
performing a physical exam, however, may be far more important in identifying easily
recognizable genetic conditions where a clinical diagnosis can be made. It will be
important to identify if the diagnostic outcome for patients seen by telemedicine and inperson is comparable given these previously reported concerns.
Our research aimed to provide insight for providers as a comprehensive
comparison study of the diagnostic yield between in-person and virtual genetics visits via
telemedicine. There have been many benefits previously reported when patients are
provided a telemedicine option, which has included an increase in efficiency, high patient
satisfaction, decrease in wait times for an evaluation, and decrease in distance required
for patient travel (Hilgart et al., 2012; Hopper et al., 2011; Lea et al., 2005; Stalker et al.,
2006). However, there is a lack of data comparing in-person and pediatric telegenetic
(live video-conferencing to provide genetic services) evaulations with a physical exam by
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a clinical geneticist. Furthermore, no published data have focused on the diagnostic
outcome when a medical professional is not present to facilitate the use of
videoconferencing technology for the patient or family to obtain the physical
examination. Given the lack of literature examining the efficacy of telemedicine in
comparison to in-person evaluations, this study generated quantifiable data to address if
there are any significant differences in diagnostic outcomes between in-person and virtual
visits. If a difference in diagnostic yield exists, it will be important to further examine
who would most benefit from a virtual visit given there have not been guidelines
established or best practices to adhere to when offering genetic services via telemedicine.
The goal of this research is to inform best practices moving forward, as it appears
that telemedicine will remain a viable alternative method to provide care to patients. As
with the goals stated in much of the literature and previous research, we aimed to
investigate ways to improve access to genetic services, decrease the time from symptom
onset to diagnosis, improve efficiency, reduce transportation and missed work barriers for
caregivers, and provide quality care with high patient satisfaction. Due to the limited
research comparing the efficacy and diagnostic outcome of telehealth visits to in-person
evaluations, we explored pre-COVID-19 in-person data to compare with post-COVID-19
telehealth data. Not only is this an important area that has yet to be explored in the
literature, it will largely determine best practices moving forward as genetic services
continue to be offered to patients virtually. Additionally, the literature in genetic
counseling services far outweigh the literature in genetic services that include a physical
evaluation. It is critical to close the gaps in our current research regarding telemedicine

25

practices in clinical pediatric genetics by highlighting both the advantages and challenges
of telegenetics.
Due to expanded coverage and reimbursement of telehealth services during the
PHE, parity in reimbursement has allowed providers included in this study to continue
seeing patients in a virtual capacity. This allowed us to compare populations seen by
these providers in-person pre-COVID-19 to those seen by the same providers virtually
post-COVID-19. Investigating the diagnostic yield has been an area that is continuously
regarded as a need for future studies in determining telegenetics as an adequate
alternative service delivery model. We hypothesized that there would not be a significant
difference in diagnostic outcomes for patients seen in-person when compared to those
seen by telemedicine. Therefore, our goal was to provide valuable insight in this area as
we hope to minimize barriers to genetic services while providing data on efficacy and
highlight what areas, if any, can be improved moving forward. Especially since reported
patient satisfaction has been notably high for virtual visits and telehealth policy changes
are beginning to catch up to technology, it is hard to imagine that telegenetics will
disappear after COVID-19 public health emergency protocols are no longer in effect.
2.2 Methods
2.2.1 Participants
This study was a retrospective review of de-identified data from electronic
medical records of patients seen at Greenwood Genetic Center (GGC). Two separate
pediatric patient populations (<21 years of age) were analyzed: “Clinical New” patients
seen in-person by a clinical geneticist during the two months prior to the implementation
of virtual visits due to COVID-19 (January and February 2020) and then virtual visits, or
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“Telehealth New” patients seen during the two months after the implementation of the
PHE protocols (April and May 2020). A total sample population of 471 pediatric patients
were analyzed in this study and categorized by visit type as either being in-person (IP) or
telehealth (TH). The group sizes were unequal, with 240 IP patients and 231 TH patients.
The goal was to determine diagnostic yield between the two patient populations. Multiple
clinical geneticists across several GGC clinics who have seen patients in-person and
virtually were included in the study for a total of six providers. Geneticists that either
specialized in metabolic genetics or only see patients virtually were omitted from this
study.
Patients seen in March 2020 were omitted from this study due to that month being
a transition period when all in-person appointments were canceled and moved to virtual
visits. Patients who were seen as a follow-up, by the metabolic clinic, by a non-geneticist,
or who were over the age of 21 years were excluded from this study. If it had been more
than 5 years since a patient had been seen by a clinical geneticist at Greenwood Genetic
Center, they were considered a New patient and included in our analysis. Six patients of
the 471 patients included had to be omitted, as they had been seen by genetics within the
past 5 years.
Reports were generated from patient electronic medical records to include the
following demographic information: visit type, no show visits, visit date, provider,
patient age, patient zip code, patient sex, patient language, and patient race.
2.3.2 Primary Indication Categories
The referral indication with the primary clinical diagnosis was used to inform the
selection of the Primary Indication for genetic evaluation. In cases where multiple
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indications were included in the reason for referral, all clinical information was reviewed,
including the primary diagnosis ICD10 code used by the geneticist, to ensure the primary
indication was selected and categorized appropriately. If the indication for testing
differed from the referral indication, the indication for testing was used as the primary
indication. For patients who had testing completed before their visit, the Primary
Indication was defined as “genetic testing completed prior to visit” and categorized as
Suspected/Known Condition.
2.3.3 Phenotypic Categorization
Other features pertinent to whether testing was or was not indicated were
categorized and recorded. This information included clinical features specifically noted
by the geneticist either in the summary of the evaluation or as a primary feature on the
test requisition. This phenotypic information was organized into 5 categories:
Neurodevelopmental Disorders, Structural Anomalies, Neurological features, Additional
Features, and Suspected/Known Condition. Neurodevelopmental Disorders included
autism, developmental delay, fine motor delay, global delay, gross motor delay, learning
delays/disability, speech delay, regression, and intellectual disability (based on
intellectual quotient (IQ) scores below 70 or a clinical diagnosis if IQ unavailable).
Structural anomalies included brain, cardiac/vascular, genitourinary/renal, craniofacial,
eye, ear, musculoskeletal, gastrointestinal, integumentary: skin, integumentary: hair/nails,
dental, and dysmorphic facies. Neurological features included abnormal muscle tone,
abnormal movements, coordination/gait abnormalities, seizures, and neuromuscular
problem. Additional Features included behavioral/psychiatric, cardiac (non-structural),
endocrine, gastrointestinal, growth, hearing loss, hematologic, joint, metabolic measures,
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ophthalmologic, prematurity/complications of prematurity, pulmonary/respiratory,
renal/urinary, and other. Finally, the last category of Suspected/Known Condition
included abnormal genetic testing prior to visit, family history of a known condition, and
suspected recognizable genetic syndrome (or rule-out suspected condition). For a full list
of conditions included in these categories, see Appendix A.
No additional clinical features were noted if prior testing was diagnostic and the
patient was being seen to establish care or receive genetic counseling by the clinical
geneticist; clinical assessment was therefore recorded and categorized as No Testing
Indicated. If prior results were deemed uninformative or did not explain all the patient’s
features, those features were recorded and clinical outcomes were recorded appropriately
based on the evaluation.
2.3.4 Clinical Assessment Categories
Patients were categorized into seven clinical assessment groups: Clinical
Diagnosis Made, Environmental, Isolated Finding, Multifactorial, Testing Indicated,
Testing Not Indicated, and Within Normal Variation. In cases where testing was not
indicated due to the availability of another more appropriate/similarly affected family
member, patients were placed in the Testing Not Indicated category. If such a patient was
tested within a six-month timeframe to confirm or rule out a variant found on family
member’s testing, their categorization was changed to Testing Indicated and the outcome
of the testing was recorded appropriately. For a full list of descriptive data that fall within
each category, see Appendix B.
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2.3.5 Genetic Testing Categories
The following testing types were included in this study: chromosome analysis,
chromosomal microarray (CMA), FMR1 repeat expansion, methylation-specific
multiplex ligation-dependent probe amplification (MS-MLPA), single gene analysis,
single gene CytoScan Xon array (deletion/duplication analysis with increased coverage of
disease-associated genes), next generation sequencing (NGS) multi-gene panel, CytoScan
Xon array of a multi-gene panel, focused exome custom gene panel (including 2 or more
genes by the ordering provider), focused CytoScan Xon array (including 2 or more genes
by the ordering provider), whole exome sequencing (WES), and target analysis
(including both targeted sequencing and targeted array). Biochemical testing was not
included in this analysis unless it led to a molecular diagnosis, in which case the primary
phenotypic indication for evaluation and testing was classified under “metabolic
measures.”
2.3.6 Diagnostic Outcome
For patients whose clinical assessment was Testing Indicated, records about the
type of testing ordered and the results were reviewed. Due to the need to obtain insurance
prior authorization for testing or other possible logistical delays, any genetic testing
ordered at GGC within six months of the visit was analyzed. In the case of a sample
failure requiring repeat collection and analysis, the timeframe to review the test results
was extended to eight months. Any subsequent testing or second tier testing ordered
within four months of the initial result return were also reviewed. No second-tier testing
was reviewed after ten months from the time of the patient’s initial visit.
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Test results were categorized as follows: Diagnosed, Undiagnosed, Uncertain, and
Not Completed. Diagnostic results included pathogenic, likely pathogenic, or variants of
uncertain significance results that were determined to be clinically relevant to the primary
indication. A likely pathogenic or pathogenic result with variable expressivity was also
recorded as a diagnostic result. Undiagnosed patients had lab results that were either
normal, included a secondary finding not relevant to the primary indication, or a result
that was only felt to be partially clinically relevant. Uncertain results included variants of
uncertain significance (VUS) that were either true uncertain variants or not felt to be
clinically relevant VUSs. In cases where results could not clearly be categorized as
diagnostic or non-diagnostic, clinical interpretation was ascertained from clinical or
laboratory documentation within the patient’s electronic medical record, such as in the
case of a VUS felt to be causative, or a pathogenic alteration in a gene associated with a
condition not relevant to the primary indication. If there was no documentation by the
ordering provider indicating a strong suspicion that a VUS was felt to be clinically
relevant or felt to not be clinically relevant to the patient’s features, the results were
classified simply as unknown significance under the Uncertain category.
Lastly, if testing was indicated but the patient’s sample was not returned, there
was an insurance coverage-related issue, a parent/guardian deferred testing, the provider
deferred testing, sample failure occurred, or a patient was lost to follow-up, they were
categorized as “testing was not completed” category. For a full list of descriptive data
that falls within each category, see Appendix C.
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2.3.7 Statistical Analysis and Statistical Methods
For patient records that met the inclusion criteria during the timeframe studied,
240 consecutive new in-person patient visits conducted during the months of January and
February 2020 were reviewed and 231 consecutive new virtual visits during the months
of April and May 2020 were reviewed. Patient records were reviewed to collect relevant
clinical, medical, and laboratory data including the primary indication, phenotype,
clinical assessment, genetic testing, and diagnostic outcome. Categorization was made
based on clinical and laboratory documentation in the medical records. Collected
information was used to determine relationships between the two groups (in-person visits
and telehealth visits), ensure groups are comparable in complexity, and investigate any
significant correlations that may impact the results identified in our primary objectives.
Categories were analyzed to determine if the presence of any of these features
were more likely to be associated with a diagnosis, as well as ensure that the study groups
had a similar distribution of primary indications for genetic evaluation. For patients that
did not have genetic testing, Clinical Assessment was used to determine the likelihood a
clinical diagnosis could be made with the results used to compare the patient populations
analyzed.
A database in Microsoft Excel was used to store data obtained from the patient
chart abstractions. Categorical data from patient electronic medical record were coded
and recorded into the Excel database to the corresponding patient. This was completed by
the same individual for all patients included in this study to ensure consistency. Once
completed, de-identified data were exported to IBM Statistical Package for Social
Sciences (SPSS) for quantitative analysis. Descriptive statistics, using percentages and
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frequencies, were calculated based on the collected categorical data. Pearson’s Chisquare Test of Homogeneity was used to compare variables and statistical significance
was determined from a two-tailed exact value. A two-tailed T-Test was used for
quantitative analysis to compare ages of patients included in the study. Figures and tables
were constructed using SPSS and Microsoft Excel.
2.4 Results
Based on the clinical assessment conducted by a clinical geneticist, 70 patients
(14.9%) received a clinical diagnosis based on exam, and 56 patients (11.9%) received a
diagnosis based on genetic testing that was ordered following a clinical examination. One
hundred and twenty-six patients (26.75%) in total received a diagnosis either based on
clinical examination or through genetic testing. The outcome for all patients can be seen
in Figure 2.1.
Demographic information was ascertained and used for analysis to determine
variations between the patients seen by TH when compared to those seen IP. The
information that was abstracted for review included Age, Gender, Race, Ethnic group,
and Primary Indication (Table 2.1).
An independent-samples t-test was run to determine if there were differences in
the mean ages of pediatric patients based on visit type. Age ranges were normally
distributed, and there was homogeneity of variance, as assessed by Levene’s test for
equality of variances (p = 0.204). The mean age of IP patients (M = 4.35, SD = 4.715)
was less than the mean age of TH patients (M = 4.65, SD = 5.253), though no statistically
significant difference was found between the two populations, M = 0.291, 95% CI [-1.19,
0.61], t(469) = 0.204, p = 0.527.
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A Chi-square test of homogeneity was conducted between visit type to determine
statistical significance within the ascertained demographic categories. Patient counts for
each category as well as corresponding statistical analysis can be seen in Table 2.1. With
expected cell counts that were less than five in Race and Ethnic Group categories, Egon
Pearson N-1 Chi-square corrected test was conducted to analyze differences between visit
types. Statistical significance was determined for Ethnic Group (N – 1 c2 (1) = 8.995, p =
0.003), as assessed by N-1 Chi-square test.
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Clinical
Assessment
(n=471)

Diagnoses based
on assessment
(n=70)
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Clinical
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(n=16)
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(n=24)

Multifactorial
(n=12)
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Indicated
(n=289)
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(n=18)

Within Normal
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(n=38)

Diagnostic
(T1: n=42)
(T2: n=14)

Undiagnosed
(n=233)

Normal, benign,
or only partially
relevant
(T1: n=153)
(T2: n=23)

Uncertain results
(T1: n=32)
(T2: n=5)

Testing not
indicated
(n=67)

Testing not
completed
(n=62)

Figure 2.1 Outcomes for all 471 patients included in this study. Testing outcomes were split up between the
number of patients with the corresponding outcome found on Tier 1 (T1) testing or Tier 2 (T2) testing.

Table 2.1 Comparison of demographic data between IP and TH patients

Characteristic

Visit Type
In-Person Telehealth

Age in Years M (SD)

4.35 (4.72)

4.65 (5.25)

Gender n (%)
Male
Female

157a (54.1)
83a (45.9%)

133a (45.9)
98a (54.1)

290 (61.6)
181 (38.4)

c2 (2) = 3.058
p = 0.08

208a (86.7)

221a (95.7)

429 (91.1)

30a (12.5)
2a (0.8)

8b (3.5)
2a (0.9)

38 (8.1)
4 (0.8)

c2 (2) = 12.96a
p = 0.002

5a (2.1)
41a (17.1)

2a (0.9)
52a (22.5)

7 (1.5)
93 (19.7)

29a (12.1)
151a (62.9)
6a (2.5)
1a (0.4)
7a (2.9)

7b (3.0)
147a (63.6)
9a (3.9)
3a (1.3)
11a (4.8)

36 (7.6)
298 (63.3)
15 (3.2)
4 (0.8)
18 (3.8)

Ethnic Group n (%)
Non-Hispanic or NonLatino
Hispanic or Latino
Refused/Declined
Race n (%)
Asian
Black or African
American
Hispanic
White or Caucasian
Biracial or multiracial
Other
Unknown

Overall
Sample

Statistical
Analysis
N=471
t(469) = 0.633
p = 0.527

c2 (6) = 18.409
p = 0.005

Clinical Indication for Genetic
Evaluation n (%)
Neurodevelopmental
122a (51.9) 127a (55.2) 249 (52.9)
c2 (4) = 4.361
Disorders
p = 0.359
Structural Anomalies
39a (16.6)
34a (14.8)
73 (15.5)
Neurological Features
16a (6.8)
8a (3.5)
24 (5.1)
Additional Features
19a (8.1)
26a (11.3)
45 (9.7)
Suspected/Known
39a 16.6)
35a (15.2)
74 (15.7)
Condition
Corresponding statistical analysis per comparison is located in the far-right column, with
statistically significant differences identified between the two populations based on
Timing of Visit (p < 0.001), Ethnic Group (p = 0.002), and Race (p = 0.005).
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PRIMARY INDICATIONS
Neurodevelopmental Disorders

16%

Structural Anomalies

10%
53%

Neurological Features

5%
Additional Features

16%

Suspected/known condition

Figure 2.2 Total percentage of patients seen for a genetic evaluation based on indication

Primary patient indications were additionally analyzed to determine the
proportions of broad indication groups and clinical assessment outcomes. The proportion
of patient indications found in each clinical assessment category was determined to be
significant, p < 0.001. The distribution of patients found in each category can be seen in
Figure 2.3. Descriptive data regarding the differences in outcomes based on phenotypic
indications can be found in Appendix B.
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Genetic Evaluation Outcomes Based on Indication
Testing Indicated
Testing Not
Indicated
Within Normal
Variation

Neurodevelopmental Disorders
Structural Anomalies

Isolated

Neurological Features
Multifactorial

Additional Features

Environmental

Suspected/Known Condition

Clinical
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Figure 2.3 Clinical assessment outcomes based on patient primary indication
Further assessment in comparing patients’ primary indication categories and
genetic testing outcomes identified a statistically significant difference in proportions, as
assessed by Chi-square test of homogeneity, p = 0.001 (Table 2.2). Statistical significance
was determined with corrected values (N – 1 c2 = 13.285, p < 0.001). Diagnostic yield for
each of the primary categories was determined. Statistical significance was observed for
two of the primary indications that received a diagnostic result from genetic testing:
Neurodevelopmental Disorder and Suspected/Known Condition. Twenty-five patients
(44.6%) out of the total 56 patients who received a diagnosis based on genetic testing had
a primary indication of Neurodevelopmental Disorder, which was lower than the
expected diagnostic outcome (15.0% vs. 19.4%). The other primary indication that was
determined to have a statistically significant diagnostic yield was in the
Suspected/Known Condition category, where 15 patients (26.8%) out of the total 56
patients received a diagnostic outcome based on testing, which was higher than the
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expected outcome (46.9% vs. 19.4%). Additional diagnostic testing yield based on
indication can be seen in Table 2.2.
Table 2.2 Diagnostic Yield Outcomes Based on Patient Primary Indication

Primary Indication
Category

Diagnostic Testing Results
Not Diagnostic Diagnostic
N= 233
N=56
(80.6)
(19.4)

Total
Sample
N=289

Pearson
Chi-Square
N=289
c2 (4) =
18.157
p= 0.001

Neurodevelopmental
Disorders n (%)

142a (85.0)

25b (15.0)

167
(57.8)

Structural Anomalies
n (%)

39a (84.8)

7a (15.2)

46 (15.9)

Neurological Features
n (%)

18a (78.3)

5a (21.7)

23 (8.0)

Additional Features n
(%)

17a (81.0)

4a (19.0)

21 (7.3)

Suspected/Known
Condition n (%)

17a (53.1)

15b (46.9)

32 (11.1)

Differing subscripts denote statistically significant differences. NDD were found to have
a diagnostic yield statistically significantly lower than expected. Suspected/Known
Conditions were found to have a diagnostic yield statistically significantly higher than
expected yield. No statistical significance was detected in remaining indication groups.
To determine variations in clinical assessment outcomes, a corrected N-1 Chisquare (2 x c) was conducted between visit type and the outcome of the genetic
evaluation clinical assessment, with two expected cell counts less than five. Statistical
significance difference in proportions, as assessed by N-1 Chi-square test, p < 0.001, was
found in two out of the seven clinical assessment categories (Table 2.3). The proportion
of patients classified as having an isolated feature or as being within normal variation was
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statistically significantly lower in the telehealth population, p < 0.05. The proportion of
patients in all remaining categories were not found to be statistically significant.
Patients were determined to have a diagnosis of an isolated feature in 15 patients
(83.3%) with an in-person visit compared to 3 patients (16.7%) with a telehealth visit. In
the patient population determined to be within normal variation based on clinical
assessment, 27 in-person patients (71.1%) were identified compared to 11 telehealth
patients (28.9%).
Table 2.3 Clinical assessment outcomes found in both IP and TH patient population
Clinical Assessment
Outcome

Visit Type
In-Person
Telehealth
N= 235
N=229

Total
Sample
N=464

Chi
Square
N=464
c2 (6) =
19.97
p = 0.003

Clinical Diagnosis of
Genetic Condition n (%)

7a (3.0)

9a (3.9)

16 (3.4)

Environmental Etiology
n (%)

15a (6.4)

9a (3.9)

24 (5.2)

Multifactorial Etiology
n (%)

4a (1.7)

8a (3.5)

12 (2.6)

Isolated
Feature/Anomaly n (%)

15a (6.4)

3b (1.3)

18 (3.9)

Within Normal
Variation n (%)

27a (11.5)

11b (4.8)

38 (8.2)

Testing Not Indicated n
(%)

28a (11.9)

39a (17.0)

67 (14.4)

Testing Indicated n (%)

139a (59.1)

150a (65.5)

289 (62.3)

The percentages, as seen in parentheses, indicated the percentage of the total visit type
populations (IP, TH, or of the total sample size). Chi square testing was used to
determine significance. Differing subscripts indicate the outcomes with statistically
significant difference in values, as seen in Isolated Feature/Anomaly and Within Normal
Variation.
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The overall clinical diagnostic yield, based on patients who had clinical
assessment outcomes categorized as Clinical Diagnosis Based on Exam, Environmental
Etiology, Multifactorial Etiology, or Isolated Feature were analyzed to determine
percentages in TH and IP clinical diagnoses. The total number of patients receiving a
clinical diagnosis was 70 out of the 464 patients included in this study for an overall
diagnostic yield of 15.1%. The number of patients seen in-person that received a clinical
diagnosis was 41 out of a total of 235 patients, resulting in a 17.5% yield. In comparison,
29 patients seen by telehealth were found to have a clinical diagnosis out of a total of 229
patients, resulting in a 12.6% diagnostic yield.
Of the clinical assessment outcomes, Isolated Feature/Anomaly and those found
to be Within Normal Variation were diagnosed in a significantly higher number of IP
patients in comparison to patients seen by TH.
Descriptive details, which can be found in Appendix B, found that IP patients
with a clinical assessment outcome of Isolated Feature/Anomaly had a majority of
primary indications falling in the Structural Anomaly category, with most patients
identified to have Craniofacial Anomalies (6), followed by Structural Heart Anomaly (2)
and Gastrointestinal Anomalies (2). In total, 15 patients in the IP population were
diagnosed with an Isolated Feature/Anomaly, 13 of which had a primary indication
classified as Structural Anomaly. The other patient had a primary indication of a
Recognizable Genetic Condition, specifically to rule out McCune-Albright syndrome but
was found to have isolated precocious puberty due to ovarian cysts. In comparison, only
three total TH patients received a clinical diagnosis of Isolated Feature. One patient with
a primary indication of Neurodevelopmental Disorders had developmental delay that was
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documented by that provider to be a result of benign enlargement of subarachnoid space
(BESSI)-related macrocephaly. The other two patients were categorized to have
Structural Anomalies, specifically Structural Heart Anomaly.
A majority of patients that were felt to be Within Normal Variation were
identified to have Neurodevelopmental Disorders in both IP (19/27 patients, 70.4%) and
TH (6/11 patients, 54.6%) visits. About half of the IP patients with a
Neurodevelopmental Disorder had Developmental Delay (9/27 patients; 33.3% of the
total), while the others had Speech Delay (10/19 patients; 37.0% of the total). This
distribution was similar in the TH patients as well, with half of the patients having
Developmental Delay (3/11 patients; 27.3% of the total) and the other half having Speech
Delay (3/11 patients; 27.3% of the total). The next most common indication present in the
IP patients found to be Within Normal Variation was identified in patients with
Additional Features; specifically, those classified as having Joint Problems (3/27 patients;
11.1%). Upon clinical assessment, these patients were not found to meet criteria for
hypermobile Ehlers-Danlos syndrome (hEDS). Only one patient with Joint Problems in
the TH patient population was felt to be Within Normal Variation for this same reason
(1/11 patients; 9.1%). Interestingly, the TH population with a primary indication of Joint
Problems was observed more in Clinical Diagnosis category with a diagnosis of benign
joint hypermobility syndrome; a total of five patients (5/9 patients; 55.6%) fell into this
clinical assessment outcome. In addition, one patient with an indication of Recognizable
Genetic Condition received a clinical diagnosis of benign joint hypermobility syndrome
after hEDS was ruled out on exam. In comparison, only three IP patients received a
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clinical diagnosis for Joint Problems (3/7 patients; 42.9%). More details regarding
descriptive details of the clinical assessment can be found in Appendix B.
In the 38 total patients identified that were found to be within normal variation,
65.8% had a primary indication of Neurodevelopmental Disorder, with a higher number
of IP patients receiving this clinical outcome (19/38 IP patients vs 6/38 TH patients).
The primary indications of patients who were categorized as Testing Indicated or
Testing Not Indicated were not analyzed because no differences were observed in those
assessment outcomes between the TH and IP populations.
Genetic testing was indicated in a total 289 patients, with 139 IP patients and 150
TH patients. The distribution of this group can be seen in Figure 2.1. Additional analysis
using Chi-square test of homogeneity was used to compare testing outcomes between IP
and TH patients. Note that only 227 patients were analyzed, as 62 patients failed to
complete testing (35/62 TH patients, 27/62 IP patients). Analysis of tier 1 testing
outcomes found there to be no statistically significant differences in the proportions of
patients who received a diagnostic, non-diagnostic, or uncertain result based on testing
performed in patients seen in-person when compared with those seen by telehealth, p =
0.938. Of the 227 patients who had genetic testing, a total of 42 patients were found to
have an underlying genetic cause for their features for a tier 1 diagnostic yield of 18.5%.
Twenty-one of those patients were seen by TH (18.4% TH diagnostic yield) and twentyone patients were seen IP (18.6% IP diagnostic yield). Similarly, the same analysis was
performed for tier 2 testing in those patients who remained undiagnosed following tier 1
testing (n = 42). Statistical significance was not identified in the proportion of patient
testing outcomes when comparing patients seen IP to those seen by TH (Figure 2.4). The
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diagnostic yield for patients receiving tier 2 testing was 31.8% TH compared to 35.0%
IP. Additional testing details regarding test strategy and descriptive data based on
phenotypic descriptions in each primary indication group can be found in Appendix A
and D.

Genetic Testing Outcomes
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Figure 2.4 Genetic testing outcomes as determined by either first or second tier tests.
Patients who received either a clinical diagnosis based on exam or received a
diagnostic result following genetic testing were reviewed to determine the overall
diagnostic rate for patients seen in-person compared to patients seen by telehealth
(Figures 2.5 – 2.6). The overall diagnostic yield for both groups was 27.1%, with the inperson diagnostic yield being 29.2% and telehealth diagnostic yield being 24.9%. There
was no statistical significance between IP and TH patient populations regarding the
overall diagnostic yield, as assessed by Chi-square test of homogeneity, p = 0.292.
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Combined Diagnostic Yield
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Figure 2.5 Comparison of IP and TH patients based on the combined diagnostic yield to
include diagnoses made by clinical exam or diagnostic testing.
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Figure 2.6 Comparison of the percentage of IP, TH, and total patient population and
corresponding diagnostic outcomes.
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2.5 Discussion
2.5.1 Demographic Differences
To determine if the diagnostic testing outcomes were truly not statistically
significant, due to either differences in patient demographics or indications for a genetic
evaluation, we further investigated variations between the in-person and telehealth
populations. Age groups, gender, and clinical indications were not significant when
comparing the two types of visits. There was, however, a significant decrease in patients
who reported their ethnicity as Hispanic/Latino that were seen by TH when compared to
IP (TH = 3.5% vs. IP = 12.5%, p = 0.002). Unsurprisingly, this difference was also
identified in the patient’s reported race, with 12.1% of those identifying as Hispanic seen
by an in-person evaluation, and 3.0% of those identifying as Hispanic seen by a telehealth
evaluation (p = 0.005). Non-Hispanic or Non-Latino patients as well as all other races
included in this study were comparable between the two groups.
Although we did not investigate details to support this theory, the smaller number
of Hispanic patients seen by telehealth may in part be due to challenges in incorporating
an interpreter into a telehealth visit, as opposed to a technology barrier within this ethnic
group. GGC has historically utilized in-person interpreter services during in-person
appointments; however, non-urgent appointments requiring translation services were
temporarily put on hold during the transition of all in-person visits to telehealth visits in
the COVID-19 pandemic to allow providers to get acclimated to telehealth. Since the
transition, interpreter services can be used during virtual visits but there are logistical
challenges so IP visits are typically preferred. Further investigation into the underlying
barriers leading to discrepancies due to demographics as it pertains to the Hispanic or
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Latino population may help elucidate the reasons behind this variation. Additionally,
once identified, it would provide new insight into whether this is a result of a lower
uptake of telemedicine services based on race or ethnicity or if this variation is the result
of clinic-driven procedures. Identifying and reducing the underlying barriers would serve
to better provide equitable telehealth services to the Hispanic or Latino population.
No significant difference was found in the distribution of primary patient
indications seen by TH when compared to those seen IP. The importance of the inclusion
of this analysis was that we did identify significant difference in clinical assessment
outcomes as well as diagnostic yield based on indication. A clinical diagnosis of an
Isolated Feature/Anomaly was more likely to be given in the IP cohort. Additionally, we
determined that a majority of the patients with isolated features were categorized as
having a primary indication of Structural Anomaly. Given the distribution of patients
seen with a primary indication of Structural Anomaly (16.6% IP vs 14.8% TH) was not
significantly different, we can infer that it is unlikely that the discrepant Isolated
Feature/Anomaly diagnosis based on clinical assessment is attributed to unequal
distribution of a primary indication of structural anomalies in each visit type, though one
cannot entirely rule it out given our population size.
Similarly, with the difference seen in TH and IP patients who were determined to
be within normal variation based on clinical assessment, we can infer this was not a
consequence of unequal distributions of patients based on primary indication. The
difference in TH and IP clinical assessment outcome found to be within normal variation,
may in part be due to provider comfort in making this call without seeing the patient for
an IP physical examination. Further research may be needed to determine if the decrease
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in this clinical assessment outcome in the TH population is uniform across all providers,
or if this may be more common in some providers over others. Additionally, this could be
an area of interest in creating telemedicine workflows, protocols, and training aimed at
minimizing differences seen in clinical assessment outcomes between IP and TH visits.
2.5.2 Outcomes based on clinical assessment
The goal of this study was to evaluate any difference in diagnostic outcomes for
patients seen by telehealth when compared to those seen in-person. Much research has
been done to assess and compare provider and patient satisfaction rates between
telemedicine and in-person evaluations. Stalker et al. (2006) determined some of the
provider concerns in utilizing telemedicine, specifically, as it pertains to being able to
perform an adequate clinical evaluation to make a diagnosis based on phenotypic
findings. For that reason, we analyzed the patient outcomes of clinical assessments done
in-person and compared them to those done by a telehealth visit.
The overall clinical diagnostic yield, based on patients who had clinical
assessment outcomes categorized as Clinical Diagnosis Based on Exam, Environmental
Etiology, Multifactorial Etiology, or Isolated Feature were analyzed to determine
percentages in TH and IP clinical diagnoses. We saw a different clinical diagnostic yield
between the IP and TH groups. While this difference was not statistically significant, we
thought of several reasons as to why these numbers may vary. One of these reasons is
that multiple providers were included in this study and provider documentation was relied
on to determine the categorization of the evaluation outcome. Therefore, differences in
provider-specific diagnostic yield and clinical assessment outcomes may have
contributed to the differences seen in assessment outcomes. It is also important to
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consider that some providers may have not seen an equal proportion of TH patients
following the transition from IP visits.
The differences observed in Isolated Features between the two populations may
be the result of difficulty distinguishing a feature as isolated without an in-person
examination. Phenotypes within the Structural Anomaly category, such as congenital
heart defects (CHD) or other major malformations, may be easier to report as isolated in
the absence of other malformations, dysmorphism, or family history; however, this may
be more difficult to determine without an in-person physical examination for patients
with minor anomalies (e.g. ear tags, cleft lip +/- cleft palate, etc). Additionally, many
isolated anomalies are felt to be multifactorial and therefore would be provider-dependent
on whether it is documented as isolated vs. multifactorial. The lower number of TH
patients categorized as having isolated features based on clinical examination may have
signified that providers were more willing to pursue genetic testing to rule out genetic
etiology as opposed to relying on a virtual examination. Although we investigated the
diagnostic yield as it pertains to primary indication, we did not explore differences in
testing strategies based on indication in the IP and TH populations.
Future studies could seek to identify if the slight increase in number of TH
patients who were found to have either testing indicated, or not indicated were due to a
higher number of patients with Neurodevelopmental Disorders receiving either of these
clinical assessments. It may be that a provider was more likely to determine Testing Not
Indicated for reasons that are described as Wait-and-See Approach, as described in
Appendix C. It could also be that a provider feels more comfortable following-up to
ensure developmental progress is made, rather than documenting whether or not they felt
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the patient fell in the Within Normal Variation category. Given our TH population was
ascertained in the immediate two months following the onset of the PHE, these patients
may have had developmental therapies interrupted, thus making it more difficult to
determine if developmental progress had been made.
It is unclear if variations observed between the two patient populations as a
consequence of our population size, different testing strategies based on clinical
indication, provider differences in documentation, or if this is a result of previously
mentioned trepidation amongst providers in performing a clinical evaluation by telehealth
(Hilgart et al., 2012). In the study by Lea et al. (2005), familiarity and comfort with
telemedicine technology was a way to improve provider confidence in offering
telegenetic services. This may be an interesting area to expand on in future research.
2.5.3 Genetic Testing Outcomes
As expected in our hypothesis, we did not identify a difference in diagnostic yield
of genetic testing for patients that were seen in-person prior to the COVID-19 public
health emergency protocols when compared to the patients who were seen after the
transition to seeing patients virtually.
Given the distribution of primary indications for patients that were seen by
telehealth and in-person were similar, we can infer that this outcome is not an artifact of
uneven distribution of patients with an indication that would have a significantly higher
yield of a diagnostic outcome in one group over the other.
Our results were consistent with previous studies analyzing the diagnostic yield of
genetic testing in patients with a variety of phenotypic indications. For both populations
that were compared in our analysis, our diagnostic outcomes (~18.5%) were similar to
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those previously observed around 15-20% in patients with indications including MCA,
DD/ID, and ASD (Miller et al., 2013). Similarly, tier 2 testing in our patient population
had an overall diagnostic yield of 33.3%, which is consistent with literature suggesting
that a diagnostic yield may be as high as 40% in those with a targeted sequencing
approach following exam, testing performed in those with a family history suggestive of
a genetic diagnosis, or tier 2 testing in those whose initial testing fails to identify an
underlying genetic cause (Kiely et al., 2016).
These data support our hypothesis and suggest that a pediatric genetic evaluation
performed by telehealth is as effective in determining a diagnostic outcome from a testing
perspective.
2.5.4 Combined Diagnostic Yield
Although a statistically significant difference was found in two of the seven
possible clinical assessment outcomes, this did not impact the final combined diagnostic
yield (clinical diagnostic outcomes and genetic testing outcomes) in comparing IP and
TH patients. No statistical significance was determined; however, a slightly higher
number of IP patients received a diagnostic outcome (69 patients; 14.8%) when
compared to the TH population (57 patients; 12.3%). This outcome is consistent with our
hypothesis that a statistically significant difference would not be found between patients
seen IP when compared to those seen by TH. Previous studies that have reviewed the
diagnostic effectiveness resulting from a video-conference telegenetics examination in
the pediatric setting support that it is unlikely that a provider would miss a diagnosis
based on different modalities alone (Lea et al., 2000; Stalker et al., 2006). Our results
suggest that it is unlikely a diagnosis would not be made solely based on the patient’s
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visit-type; however, a provider may be less likely to definitively document whether or not
a patient’s features are within normal variation or felt to have no underlying genetic
etiology when not undergoing a physical examination in-person.
2.5.5 Telehealth as an Alternative Service Delivery Model
The primary goal of this study was to determine if telehealth is an adequate
alternative service delivery model for pediatric patients receiving clinical genetic
evaluations. With the previously mentioned barriers such as distance to provider, travel
distance, financial burdens, including missed work and childcare for other children, as
well as the addition of COVID-19-related barriers, finding opportunities to make genetic
services more accessible is a primary focus. With our results identifying similar overall
diagnostic outcomes for both telehealth and in-person pediatric genetic evaluations, it
would be reasonable for institutions to consider telegenetic evaluations as a comparable
alternative to an in-person genetic evaluation.
This study found no difference in diagnostic yield between TH and IP visits;
however, larger studies in the future could provide additional support for our findings.
Further investigation into the discrepancies in clinical diagnoses may provide valuable
insight into the differences identified in this study. Given differences in testing outcomes
were not observed but differences were observed in some of the clinical assessment
categories, identifying patients who are most likely to have testing indicated prior to their
visit may allow those patients to be scheduled for a telemedicine evaluation due to
similarities found in diagnostic testing yield. An in-person evaluation, however, may be
more beneficial to patients whose clinical evaluation or physical examination would
determine whether or not they will receive a clinical diagnosis or if they will be found to

52

have testing indicated. For patients with a primary indication with an expected high
diagnostic yield based on testing, and a low clinical diagnostic yield (e.g. patients with a
primary indication of neurological features), telegenetics may be an equally viable, if not
better modality as opposed to an in-person evaluation. This would alternatively apply to
patients with an indication associated with a lower testing diagnostic yield, whose clinical
assessment may be more suitable for an in-person evaluation.
2.5.6 Limitations
A limitation in the collection of data used to conduct this study was that much of
the phenotypic data used to determine the primary indication were subjective. To
ameliorate some of the subjectivity in determining primary indication, broad groupings
were established to aid in interpretation. If the primary referral indication did not match
that of the primary testing indication, the primary testing indication was the indication
used for this study. This was based on the primary ICD-10 code classification that was
decided on by the ordering physician at the time testing was ordered. When patients had
multiple indications, the primary indication based on ICD-10 codes was used.
Testing strategy was recorded in the abstraction of data from EMR; however, we
did not analyze the differences in strategies between the two populations. Differences in
testing strategy may alter the diagnostic yield based on indication for which that testing
strategy was implemented. The descriptive information that was collected can be found in
Appendix D.
Additionally, this study did not analyze provider differences regarding
distribution of in-person and telehealth patients per provider, likelihood of diagnostic
outcomes, and differing testing strategies by provider. Provider differences may impact
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the interpretation of the results found in this study, if certain providers with altering
practice strategies between IP and TH visits have an uneven distribution of the different
populations used for this study. This may also be the case with respect to differences
made in providers’ documentation. Given that the categorical assignments were based on
providers’ documentation, clinical assessment outcomes may differ significantly even for
the same phenotypic indication. This can be most notable in the qualitative differences in
which an indication, such as Joint Problems, was assigned differing clinical outcomes
despite similar indications. Some providers documented clearly in the EMR for patients
being seen to rule out hEDS, that the patient outcome was Within Normal Variation (or
did not meet criteria), whereas others instead determined patients to have benign joint
hypermobility syndrome, thus their categorization as Clinical Diagnosis. Differences in
documentation could therefore affect the differences seen in clinical outcomes based on
assessment for patients included in this study.
Finally, time constraints limited the number of patients included in this
comparison analysis. Some categories included in our analysis to determine clinical
assessment outcomes for comparison had values that were less than five. Due to the small
sample size, the external validity of testing may not necessarily be generalizable to that of
the general population. Future analysis involving larger sample sizes for comparison
would aid in determining if some of the statistically significant differences identified can
be replicated in a larger sample size.
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CHAPTER 3
CONCLUSION
Given the many benefits for both patients and providers that have been previously
studied in using telemedicine for patient care, our research provides further justification
for the use and utility of telegenetics as a means to provide genetic services across a
broad range of pediatric patients seeking genetic evaluations. Telemedicine continues to
be an area of interest across many medical specialties in making healthcare more
equitable, available, and accessible. Though much of the research has been surrounding
the satisfaction of patients and providers in these alternative delivery services, the
literature has been lacking quantifiable data that would suggest similar outcomes for
patients receiving telegenetic services when compared to those who have received inperson genetic services. The data generated by our research suggest that the efficacy of
pediatric telehealth visits would not differ significantly from that of an in-person genetic
evaluation in terms of the overall diagnostic outcomes. Though more studies are needed
to determine the differences that can be seen in clinical assessment outcomes, our
research provides support that these differences did not affect the diagnostic outcome.
Implementing successful telegenetics programs has largely been constrained by
limitations in reimbursement from health insurers when compared to in-person
evaluations. The low reimbursement rates have also contributed to limited research in the
effectiveness of telehealth programs as it pertains to diagnostic outcomes across
specialties, and has been cited in a number of other studies as a limiting factor in the
55

sustainability of maintaining telegenetics as an option for patients seeking genetic
services (Hilgart et al., 2012; Lea et al., 2005; Terry et al., 2019). With the expansion of
services covered by CMS during the COVID-19 PHE, telemedicine as a whole has made
a considerable footprint in how healthcare providers can provide services to patients.
With the previous literature suggesting high satisfaction rates among patients and
providers, it is unlikely that this increasingly popular alternative service model will
disappear once the PHE is over. This study supports telegenetics as a comparable
alternative to in-person evaluations moving forward. Additionally, the differences
between the two populations that were highlighted in our results identify areas of needed
improvement and future research in order to minimize provider limitations and patient
barriers in future provision of telegenetics services
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APPENDIX A
PRIMARY INDICATIONS WITH SUBGROUPS
Developmental Delay
Global Delay
Speech Delay
Fine Motor Delay
Gross Motor Delay
Autism
Intellectual Disability
Learning Disability
Regression
Brain

Congenital heart defects
(CHD)/Cardiac/vasculature

Genitourinary/renal Anomalies

Craniofacial

Eye

Musculoskeletal

Neurodevelopmental Disorders
Unspecified
Speech, fine motor, gross motor, cognitive, personal/social
(Needs to have delays in 2 or more of domains listed above)
Unspecified, expressive, receptive, mixed, apraxia, dyspraxia, articulation
Unspecified
Unspecified, non-ambulatory
Diagnosis based on ADOS
IQ <70 or a clinical diagnosis of intellectual disability without available IQ
ADHD, dyslexia, “slow learner,” history of special education without a diagnosis of ID
Any history of regression in skills
Structural Anomalies
Congenital brain anomalies, abnormal MRI, agenesis of corpus callosum, cerebellar dysplasia,
enlarged cerebellum, enlarged vermis, small cysts, small peduncles, fused cerebellum,
underdevelopment of left frontal lobe, dysgenesis of corpus callosum, hypoplastic septum
pellucidum, small corpus callosum, holoprosencephaly, cortical dysplasia, dandy-walker
variant, shortened corpus callosum, cerebral ventriculomegaly, polymicrogyria, cerebellar
white matter abnormalities, periventricular leukomalacia (MRI in NICU),
hemimegalencephaly, interhemispheric brain cyst, cortical dysplasia, thin corpus callosum,
brain malformations, small cerebellum, Chiari malformation, hydrocephalus, cerebral
ventriculomegaly, cerebellar ectopia, periventricular leukomalacia found shortly after birth,
agenesis of corpus callosum, polymicrogyria, midline arachnoid cyst, schizencephaly,
periatrial heterotopias, brain stem underdevelopment, changes in cortical sulcation and
opercularization patterns, spinocerebellar atrophy, cerebral atrophy, brain tumors, brain
hemorrhage, IVH, white matter atrophy, abnormal brain MRI, leukodystrophy, brain cyst,
cerebral atrophy, benign external hydrocephalus, hemimegalencephaly, pseudotumor cerebri,
delayed myelination, leukomalacia cortical thickening, ectopic posterior pituitary gland,
glioma, focal cortical dysplasia, benign enlargement subarachnoid space of infancy
Patent foramen ovale, ventral septal defect, tricuspid valve defect, mild supravalvular aortic
narrowing, atrial septal defect, left sided superior vena cava, congenital heart defect, patent
ductus arteriosus, atrioventricular canal defect, coarctation of the aorta, short aortic arch,
tetralogy of Fallot, aortic root dilation, left ventricular enlargement, small internal carotid
artery, hypoplastic aortic arch, dilated cardiomyopathy, hypertrophic cardiomyopathy, AV
malformations, Galen aneurysmal malformations (VGAM), hemangioma (internal), lymphatic
malformation, cor triatriatum sinister, single coronary artery, pulmonic valve stenosis
Penile torsion, undescended testes, shawl scrotum, penile chordee, hypoplastic labia, genital
anomalies, cryptorchidism, hypospadias, small vaginal area, undescended testicle, small
uterus with no connection of cervix to vagina, hypoplastic vagina, ambiguous genitalia,
hydronephrosis, small right kidney, underdeveloped kidney, ureteropelvic junction
obstruction, hydrocele, thickening of the glomerular basement membrane, adrenal cysts,
duplicated collecting system, multicystic kidney
Submucosal cleft palate, cleft lip +/- cleft palate, bifid uvula, Pierre Robin sequence, cleft lip
and palate, pseudocleft of the upper lip, choanal atresia, Microcephaly, macrocephaly, relative
microcephaly, turricephalic head, dolichocephaly, trigonocephaly, acquired microcephaly,
plagiocephaly, narrow cranium, relative macrocephaly, borderline microcephaly,
micrognathia, prominent forehead, frontal bossing, craniosynostosis, macroglossia, delayed
fontanelle closure, harlequin deformity of the orbit(s), macroglossia
Chorioretinal colobomas, ocular anomalies, optic nerve hypoplasia, eye anomalies, optic
nerve hypoplasia, hypoplasia of fovea centralis, optic nerve abnormalities, optic nerve
atrophy, congenital macular scar, microphthalmia, lacrimal duct abnormality,
blepharophimosis
Skeletal dysplasia, abnormal radiographic findings, congenital scoliosis, clinodactyly, joint
contractures, club foot/feet, rhizomelia, micromelia, transverse limb defect, polydactyly,
clinodactyly, limb reduction defect, bowing of lower legs, positional scoliosis, hip dysplasia,
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Gastrointestinal
Ear

Integumentary: skin

Dysmorphic facies
Integumentary: hair/nails

Dental

Neurological- Unspecified
Abnormal Movement

Coordination/Gait/Balance
Seizures
Neuromuscular

Prematurity/complications of
prematurity
Gastrointestinal- non-structural
Joint
Behavioral/Psychiatric

Hearing Loss
Pulmonary/Respiratory
Ophthalmologic- non-structural

pectus carinatum, pectus excavatum, kyphoscoliosis, chondrodysplasia punctata, butterfly
vertebra, absent rib, underdeveloped tibias, radial clubbing of hands, scoliosis, vertebral
anomalies, low bone density, short neck, wide neck, broad neck, torticollis, branchial cleft,
sacral dimple, Short toes, 2-3 toe syndactyly, toe contractures, abnormality of foot, sandal gap
toes, webbing of toes, wideness of forefoot, pes planovalgus, broad great toes, brachydactyly,
hypoplasia of the toes, small hands, short hands, stub thumbs, single transverse palmar crease,
bridge palmar crease, horizontal crease on left hand, square-shaped thumbs, short metacarpal
bones, camptodactyly, short metacarpals, short 5th fingers, long thin tapered fingers,
brachydactyly, hypoplastic thumbs, single flexion crease on 5th fingers, adducted thumbs,
syndactyly, symbrachydactyly, Poland anomaly, scoliosis, kyphosis, knock knees
Anal atresia, TE fistula, Hirschsprung, bilateral hernia, hernia, umbilical hernia,
diaphragmatic hernia, inguinal hernia, intestinal malrotation, polysplenia, esophageal atresia,
intussusception, polyposis, intestinal perforation, septated subcapsular hepatic lobe cyst
Low set ears, abnormal cartilage of external ears, preauricular tag, over folded helices, large
ears, overfolded helices, mildly cupped ears, low set ears, dysmorphic ears, thick ear helices,
misshapen right ear, posteriorly rotated ears, simple helices, left ear abnormality with
prominent tragus/extra tissue, abnormally shaped ears, cupped ears, posteriorly rotated ears,
small ears, thick helices and antihelices, otosclerosis, earlobe crease
Café au lait, mongolian spots, hypopigmented macules, swirling pigmentation, vitiligo, ash
leaf spot, variable pigmentation of the skin, wide spaced nipples, stretchy skin, dermal
histiocytosis, irregular capillary vascular malformation of the skin, hemangioma (cutaneous),
ichthyosis, nevus flammeus, ichthyosis
Unspecified dysmorphic features of the face, eyes, ears, nose, lips, facial structure. Or
dysmorphic features include two or more dysmorphic features of the face, eyes, ears, nose,
lips, facial structure.
Increased hair on back, thick eyebrows, synophrys, abnormal hair pattern and growth, thin
hair, low anterior hairline, sparse hair in parietal areas, sparse blonde hair, increased hair on
arms, low anterior hairline, synophrys, abnormal eyebrows, nail anomalies, brittle nails,
concave nails, deepset nails, fingernail hypoplasia, hyperconvex fingernails, small nails, thin
nails
Tooth anomalies, dental anomalies, dental abnormalities, missing adult tooth, brittle teeth,
diastema in central upper incisors, wide spaced teeth, small unusually shaped teeth
Neurological Features
Unspecified, trauma, hypoxic event, nonspecific abnormal EEG (excessive background
slowing for age, etc)
jerky upper body movements, spasticity, abnormal twitching and jerking, abnormal
movements, dystonia, clonus, spastic quadriplegia, severe dystonia, tremors in hands and feet,
benign shuttering attacks, hand tremors, hyperkinesis, choreathetoid movement, spastic
diplegia, paroxysmal torticollis
Unsteady gait, episodic ataxia, abnormal ambulation, coordination impairment, waddling gait,
wide based gait, ataxia, poor balance, abnormal gait, ataxia, inability to walk, balance issues,
gait abnormality, toe-walking, mild gait imbalance, uncoordinated gait
Unspecified, generalized, myoclonic, tonic clonic, focal, absence, infantile spasms
Unspecified weakness, neuropathy, myopathy, muscular dystrophy, hyperreflexia,
hyporeflexia, increased deep tendon reflexes, absent deep tendon reflexes, muscle wasting,
myotonia
Additional Features
Born prior to 37w, apnea of prematurity, anemia of prematurity, intraventricular hemorrhage
related to prematurity, retinopathy of prematurity
GERD, GI complications, recurrent intestinal obstruction, delayed gastric emptying,
eosinophilic esophagitis, chronic diarrhea, gastroparesis, gastrointestinal dysmotility, liver
fibrosis, feeding difficulty requiring gtube, bowel obstruction
joint pain, joint laxity, stiff joints, joint hypermobility, hyperextensibility, progressive stiff
joints, multiple dislocations
Sensory processing issues, behavioral issues, anxiety, self-injurious behaviors, OCD, severe
anxiety, head banging, depression, social anxiety, behavioral issues, psychiatric concerns,
bipolar disorder, oppositional defiant disorder, under-socialized conduct disorder, aggression,
mental health issues, separation anxiety, ASD suspected clinically + failed MCHAT or STAT,
Tourette’s
Hearing loss, auditory neuropathy, sensorineural hearing loss, conductive hearing loss
Pulmonary problems, chronic lung disease, respiratory distress, congenital hypoventilation
syndrome, respiratory distress, asthma, recurrent respiratory infections, respiratory issues,
laryngomalacia
Vision loss, cortical vision impairment, severe myopia, visual impairment, retinitis
pigmentosa, FEVR, chorioretinal scarring, photophobia, pupil dilation abnormalities,
problems with tracking, lazy eye, retinal pigmentary changes, corneal abrasions, ectopic
lentis, crystalline corneal dystrophy, decreased fundus pigmentation, peripheral iris
transillumination defects, blunted foveal reflexes, decreased fundus pigmentation, abnormal
eye movements, nystagmus, exotropia, esotropia, strabismus, ptosis
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Metabolic Measures

Cardiac- non-structural
Renal/Genitourinary- nonstructural
Endocrine
Hematologic
Growth
Other
Family history
Recognizable genetic condition
Genetic testing completed by an
outside provider prior to visit

Electrolyte problems, concern for mitochondrial disorder, Low blood glucose, selective IgA
deficiency, ketotic hypoglycemia, mildly elevated CK, elevated plasma homocitrulline,
elevated lactate, hyperlipidemia, hyperglycemia, hyperphosphatemia (no known bone or renal
conditions), mitochondrial abnormalities, vitamin d deficiency, mitochondrial abnormalities,
metabolic abnormalities, elevated lactic acid, elevated alkaline phosphatase, mitochondrial
dysfunction, rhabdomyolysis, proteinuria, episodes of ketosis
Heart murmur, heart-left bundle block, bradycardia, postural orthostatic tachycardia
syndrome, LQT, rhythmic abnormality, SVT
vesicoureteral reflux, chronic kidney disease, hx kidney issues and surgeries, kidney disease,
neurogenic bladder, steroid-resistant nephrotic syndrome/FSGS/focal segmental
glomerulosclerosis, glomerulary abnormality
Hypothyroidism, thyroid disease, precocious puberty, amenorrhea, hyperparathyroidism,
congenital hypothyroidism, PCOS
Anemia, neutropenia, hematologic malignancies, epistaxis, hematemesis, thrombocytopenia
FTT, obesity, poor weight gain, rapid growth, tall stature, short stature, hemihypertrophy
Indications that do not fall within any of the other categories; multiple tumors (nonmalignant
or malignancies)
Suspected/known conditions
Known genetic condition, carrier of genetic condition, NDDs
Rule out or rule in suspected condition; patient has clinical diagnosis of genetic condition;
patient already has molecular diagnosis of a genetic condition, which was obtained by
previous testing
Patient already has a molecular diagnosis and is being seen to establish care with genetics,
patient requires genetic counseling on testing ordered by an outside provider, outside testing
results require genetic evaluation to establish clinical relevance

Figure A.1 Descriptive details found within Primary Indications
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APPENDIX B
CLINICAL ASSESSMENT DESCRIPTIVE DATA
Broad Group
Suspected/Known
Condition
Additional Features
Structural Anomalies
Broad Group
Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Structural Anomalies
Structural Anomalies
Additional Features
Additional Features
Broad Group
Suspected/Known
Condition
Neurodevelopmental
Disorders
Broad Group
Neurodevelopmental
Disorders
Structural Anomalies
Structural Anomalies
Structural Anomalies
Structural Anomalies
Structural Anomalies
Structural Anomalies
Suspected/Known
Condition
Broad Group
Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Structural Anomalies
Structural Anomalies
Additional Features

Clinical Diagnosis Based on Exam
Indication
Number of Patients
(n=7)
Recognizable Genetic
3
Condition
Joint Problems
3
Integumentary: Skin
1
Abnormality
Environmental Etiology
Indication
Number of Patients
(n=15)
Developmental Delay
9
Gross Motor Delay

1

Brain Anomaly
1
Craniofacial Anomalies
1
Prematurity
2
Growth Related
1
Multifactorial Etiology
Indication
Number of Patients
(n=4)
Recognizable Genetic
3
Condition
Autism
1
Indication
Developmental Delay

Isolated Feature
Number of Patients
(n=15)
1

Brain Anomaly
Structural Heart Anomaly
Genitourinary/Renal
Malformations
Craniofacial Anomalies
Musculoskeletal Anomalies
Gastrointestinal Anomalies

1
2
1
6
1
2

Recognizable Genetic
1
Condition
Within Normal Variation
Indication
Number of Patients
(n=27)
Developmental Delay
9
Speech Delay

10

Ear Abnormality
Integumentary: Skin
Abnormality
Joint Problems

1
1
3
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Assessment Details
oculocutaneous albinism, incontinentia
pigmenti, cleidocranial dysplasia (CCD)
benign joint hypermobility syndrome
NF1
Assessment Details
in utero drug exposure, birth trauma,
prematurity
birth trauma
birth trauma, exposures
uterine constraint
prematurity
Prematurity
Assessment Details
r/o HED (dx eczema); r/o FASD
(social/env, familial, ADHD)
prenatal exposure, complicated social/fhx,
parents with mental health
Assessment Details
isolated macrocephaly due to
ventriculomegaly
neural tube defect
congenital heart defect

polysplenia heterotaxy syndrome, isolated
gastroschisis
r/o McCune Albright- isolated precocious
puberty due to ovarian cysts
Assessment Details

does not meet criteria for hEDS

Suspected/Known
Condition
Suspected/Known
Condition

Family History

1

Recognizable Genetic
Condition

2

paternal family history X-linked condition;
patient female
r/o FASD; r/o Marfan

Figure B.1 Descriptive details regarding clinical assessment based on exam: IP
Clinical Diagnosis Based on Exam
Broad Group

Indication

Number of Patients
(n=9)
1

Structural Anomalies

Musculoskeletal Anomalies

Additional Features

Joint Problems

5

Additional Features

Growth Related

1

Suspected/Known Condition

Recognizable Genetic
2
Condition
Environmental Etiology

Broad Group

Indication

Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Additional Features

Developmental Delay

Additional Features

Assessment Details
Poland anomaly syndrome
benign generalized joint
hypermobility
growth hormone deficiency
r/o hEDS- dx benign joint
hypermobility syndrome; NF1

Number of Patients
(n=9)
3

prenatal exposure

Global Delay

1

prenatal exposure

Prematurity

2

prematurity

Behavioral/Psychiatric

1

Additional Features

Growth Related

1

Suspected/Known Condition

Recognizable Genetic
1
Condition
Multifactorial Etiology
Indication
Number of Patients
(n=8)
Developmental Delay
2

Broad Group
Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Structural Anomalies
Structural Anomalies

r/o fetal alcohol syndrome (FASD)- in
utero drug
Assessment Details
prenatal exposure, abuse, family
history
ADHD/behavioral (familial)

2

Autism

1

Speech Delay

1

Family history

Craniofacial Anomalies

1

multifactorial CL+CP and club foot

Musculoskeletal Anomalies

1

mild infantile scoliosis

Isolated Feature
Number of Patients
(n=3)
1

Indication

Neurodevelopmental
Disorders

Developmental Delay

Structural Anomalies

Structural Heart Anomaly

Neurodevelopmental
Disorders
Neurodevelopmental
Disorders
Structural Anomalies

Intrauterine growth restriction (IUGR)

Learning Delay/Disability

Broad Group

Broad Group

Assessment Details

2

Within Normal Variation
Indication
Number of Patients
(n=12)
Developmental Delay
3
Speech Delay

3

Musculoskeletal Anomalies

1

Additional Features

Joint Problems

1

Suspected/Known Condition

Family History

1

Suspected/Known Condition

Recognizable Genetic
Condition

3

Assessment Details
Macrocephaly due to BESSI- likely
contributing to delay
CHD
Assessment Details

no hypermobility present
r/o Marfan; did not meet criteria

Figure B.2 Descriptive details regarding clinical assessment based on exam: TH

67

APPENDIX C
CLINICAL AND TESTING OUTCOMES
Clinical Diagnosis
Made

Clinical Assessment Outcomes
NF1, hEDS, OCA, amniotic band syndrome, isolated growth hormone deficiency, generalized joint
hypermobility, Poland anomaly syndrome, Incontinentia Pigmenti, cleidocranial dysplasia,
hypermobility spectrum disorder

Environmental

Prematurity, in utero drug/alcohol exposures, birth trauma, growth related to IUGR, home environment,
abuse/trauma, non-nurturing early home life, neglect

Multifactorial

Behavioral/mental health related issues, eczema, learning disability (ie. dyslexia), postural
kyphoscoliosis, ADHD/behavioral (familial), clubfoot and hip dysplasia, speech apraxia, high
functioning autism
Speech delay, familial trait, delays but making progress as expected, mild joint hypermobility, within
normal variation after adjusting for prematurity, rule out Marfan syndrome
CL+/-CP, craniosynostosis, heart defect, limb defect,
polysplenia heterotaxy syndrome, neural tube defect, isolated congenital feature or structural anomaly
Follow up if no developmental progress made, no concern for genetic etiology, too low of a yield to
warrant cost of test, testing completed prior to visit from outside/referring provider, patient already has
diagnosis, path/LP/VUS found on outside testing consistent with clinical features, patient needs another
evaluation prior to testing, “wait and see” approach, initial testing more appropriate in a family
member/relative

Within Normal
Variation
Isolated
Testing Not Indicated

Testing Indicated
Diagnostic
(Includes diagnostic
results with variable
expressivity and VUS’s
felt to be clinically
significant)

Undiagnosed

Uncertain

Testing Outcome
LP Xp21.3p21.1 duplication; tetrasomy 9p (9p24.3-9p11.2); path 15q13.2q13.3 BP4-B5 loss, LP
SCN8A; trisomy 21; LP KDM5C; path mutation in EDA; 7q11.23 duplication syndrome, path 18Mb 4q
deletion; LP mutation in PTEN; de novo LP variant in ZMIZ1; 2 heterozygous path mutations in GAA;
LP variant in KDM5C; path 9.4 Mb loss of 11p15.1p14.1; de novo path MAGEL2 variant; 2 path
variants in RPGRIP1L; 18q deletion syndrome; 2 heterozygous mutations in DHCR7; path loss at
Xp22.31 assoc with XL ichthyosis; LP variant in CACNA1A (mat); path PTPN11 variant; de novo path
SLC6A1 variant; familial path APC variant; Familial variant in COL1A1 (VUS), with clinical dx of OI,
15q11.2 BP1-BP2 loss, path 15q13 BP4-BP5 deletion (mat); pathogenic mutation in TP63 associated
with ectrodactyly ectodermal dysplasia
VUS’s felt to be clinically significant: GDF2 (AD HHT type 5); FS de novo mutation in CCAR1; VUS
in NF1; pat inherited RELN VUS (dad hx sz) thought to be gene of interest; VUS in SLC6A8
(hemizygous)
Normal result- no variants detected
Secondary finding/carrier status: NDUFB3, AR mitochondrial complex I deficiency; LP NRXN1; 11p15
loss carrier for delta-beta thal; path HPS1 (hermansky pudlak I);
path mutation in SLC26A4 (pat; assoc with AR condition); carrier of path GAMT variant; LP variant in
MSH6, VUS in ALDOA gene (AR GSD XII), loss of homozygosity
Partially relevant to features: 3p26.3 491kb gain- includes exon 1 of CNTN6; VUS fs mutation in
HCN4 (assoc with arrythmias and LVNC); VUS loss at 1p35.1; 1 path variant in PDZD7 (pat), 2 VUSs
in PDZD7 (mat)
Not felt to be clinically relevant: 7p14.1 238kb gain; 4q32.1 loss; 11p13 gain; 19q11 gain; LB 4q26
gain; 1 VUS in ASPM (assoc with AR condition); VUSs: 11q13.4 (mat), Xp22.33 (pat); VUS gain of
16q24.1; VUS in MN1 (pat), VUS gain at 4p16.1, VUS gain at 6q26; VUS gain of 12q24.11 and
20q11.21; 2 VUSs: 11q14.3 gain (mat), 18q22.1 gain (pat); 2 VUSs in CLN6 and SZT2 (both assoc
with AR conditions); 81kb gain at 4q33
NLGN4X, maternal; 10q26.3 gain; RELN (mat); VUS gain of 17q24.3; VUS: 3p22.2 gain and 7q33
gain; VUS gain of 7q31.1; VUS in ASH1L, 2 heterozygous changes in SKIV2L (LP and VUS); VUS
gain of 2p25.3; 2 VUSs: 9p24.3 and 19q13.41 gains; 2 variants in cis in CDH23 (pat), 1 variant in
USH2A (mat); VUS in TANC2 (pat); VUS 7q21.1 loss; 2 heterozygous VUSs in ALDH18A1, 1 VUS in
GJC2
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Not Completed

Sample Not Returned
Insurance Related: Pre-authorization issues, pre-authorization denied, no pre-authorization ordered
Parents deferred testing: wait and see, cost, okay with just a clinical diagnosis
Loss to follow-up: did not return calls/letters for 2nd tier testing
Other: provider deferred to test a family member first, provider deferred to wait on records or present to
colleagues, there was an issue in ordering the test, sample failure, saliva kit was never sent

Figure C.1 Descriptive details found in patient clinical assessments and testing
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APPENDIX D
TESTING STRATEGIES
In-Person
Karyotype
CMA
FMR1
Single Gene
NGS Panel
Focused Panel
WES
Targeted
Karyotype + CMA
Karyotype + Single gene
CMA + FMR1
CMA + NGS Panel
CMA + WES
Karyotype + CMA + FMR1
Karyotype + CMA + NGS Panel
Karyotype + CMA + FMR1 + NGS gene panel
CMA + FMR1 + MS-MLPA
CMA + FMR1 + single gene
CMA + FMR1 + WES
Karyotype + CMA + FMR1 + WES
Karyotype + CMA + FMR1 + MS-MLPA + Single gene
Karyotype + CMA + FMR1 + MS-MLPA
Karyotype + CMA + FMR1 + single gene
Karyotype + CMA + single gene

Telehealth
CMA
MS-MLPA
Single Gene
NGS Panel
Focused Panel
WES
Targeted
Karyotype + CMA
CMA + FMR1
CMA + MS-MLPA
CMA + Single gene
CMA + NGS Panel
CMA + WES
MS-MLPA + Single gene
Karyotype + CMA + FMR1
Karyotype + CMA + NGS Panel
CMA + FMR1 + single gene
CMA + FMR1 + WES
Karyotype + CMA + FMR1 + MS-MLPA
Karyotype + CMA + FMR1 + single gene
-

Figure D.1 Tier 1 testing outcomes for IP and TH patients
In-Person
CMA
NGS Panel
Focused Panel
WES
CMA + WES
Xon array of gene panel

Telehealth
CMA
Single Gene
NGS Panel
Focused Panel
WES
Targeted + Single gene
Xon array of single gene + Focused Panel
Xon array of gene panel

Figure D.2 Tier 2 testing outcomes for IP and TH patients
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